- Datum19.05.2025
- Uhrzeit09:00 - 10:00 Uhr
- Veranstalter
XTB
Stefan Salomon
Moderator
Verona Pharma PLC Reg. Shares (Sp.ADRs) 8 o.N. Aktie
Verkaufen
Kaufen
Verona Pharma PLC Reg. Shares (Sp.ADRs) 8 o.N. Chart
Verona Pharma PLC Reg. Shares (Sp.ADRs) 8 o.N. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| TTMzero Indikation | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
2,56 %
Intraday
12,62 %
1 Woche
21,03 %
1 Monat
53,55 %
Seit Jahresbeginn
448,54 %
1 Jahr
1.643,52 %
3 Jahre
1.593,82 %
5 Jahre
Passender Service zu Verona Pharma PLC Reg. Shares (Sp.ADRs) 8 o.N.
Webinar zu Verona Pharma PLC Reg. Shares (Sp.ADRs) 8 o.N.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)11,390-74,180
- Jahrestief / Hoch ($)43,440-74,180
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Verona Pharma PLC Reg. Shares (Sp.ADRs) 8 o.N.
Keine Dividenden verfügbar
Termine von Verona Pharma PLC Reg. Shares (Sp.ADRs) 8 o.N.
Keine aktuellen Termine
Beschreibung
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
